3034 results for "Psilocybin"
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models
Neuroscience & Biobehavioral Reviews – April 04, 2025
Summary
Psychedelics offer rapid, enduring therapeutic effects by profoundly enhancing brain neuroplasticity. Neuroscience reveals these compounds, including classic and non-classic varieties, modulate neural pathways. Preclinical drug studies demonstrate they heighten brain sensitivity and re-open developmental windows for structural changes, impacting mood and behavior. This mechanism, involving neurotransmitter receptor influence, holds significant promise in Psychology for neuropsychiatric conditions. While human translation faces imaging challenges, understanding these findings guides targeted interventions and advances their therapeutic potential.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Anhedonia: Current and future treatments
Psychiatry and Clinical Neurosciences Reports – March 01, 2025
Summary
Traditional antidepressants often struggle against anhedonia, the inability to feel pleasure, which significantly impedes recovery from conditions like Major Depression. However, a diverse range of treatments offers hope. Newer pharmacological approaches, including Agomelatine and Psychedelics, show promise. Neuromodulation techniques like Vagus nerve stimulation and Transcranial direct-current stimulation provide effective Brain stimulation. Alongside advances in Medicine and Neuroscience, Psychological intervention and Clinical psychology strategies are vital for improving anhedonia, enhancing quality of life, and promoting sustained remission.
Abstract
Abstract Anhedonia is a transdiagnostic domain that leads to poor disorder outcome and low remission rates. This narrative review describes a broad...
Polysubstance Use Profiles Among the General Adult Population, United States, 2022.
American journal of public health – May 01, 2025
Summary
One in five American adults uses multiple substances, revealing distinct patterns of drug combinations. Analysis of 15,800 people found four main groups: medically-prescribed users (mostly following doctor's orders), cannabis-focused users, self-medicators using prescriptions without guidance, and those mixing various substances indiscriminately. Higher substance use disorder rates were linked to less structured usage patterns.
Abstract
Objectives. To characterize present-day polysubstance use patterns in the general adult population. Methods. From a 2022 nationally representative ...
Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action
Biological Psychiatry – March 08, 2025
Summary
A new **perspective** in **psychiatry** reveals (es)ketamine's established efficacy in **Treatment of Major Depression** and **Bipolar Disorder Treatment**. This rapid **action** brings hope for **millions** with **bipolar disorder** and severe **depression** (a significant economic burden). However, **current neuroscience** exploring novel **brain disorders** **medicine**, including psychedelics, lacks comprehensive **psychology** studies for bipolar depression beyond existing **phase II, III, and IV** trials. A **psychotherapist** might also consider **tryptophan**'s role.
Abstract
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, p...
Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2024
Summary
Common anti-anxiety medication may diminish the benefits of psychedelic therapy for depression. When lorazepam was given before psychedelic treatment, it reduced both the strength and duration of antidepressant effects. This suggests that combining these medications could make psychedelic therapy less effective, an important finding for developing future depression treatments.
Abstract
Psychedelics such as psilocybin have been shown to have persistent antidepressant effects, but with considerable individual variability in optimal ...
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2024
Summary
American psychiatrists have dramatically shifted their views on psychedelics, with 81% now believing hallucinogens show promise in treating mental health conditions. A recent survey reveals growing acceptance of psychedelic-assisted therapy among mental health professionals, with half planning to offer these treatments once approved. Psychiatrists showed increased optimism and decreased concern about risks compared to 2016, with over 90% supporting further research into therapeutic applications.
Abstract
Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression...
Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2024
Summary
As psychedelic use rises among Americans, proven harm reduction strategies are helping people navigate these powerful substances more safely. Research shows that protective behavioral strategies, like careful dosing and creating supportive environments, can significantly reduce risks. Users who implement these practices report fewer negative experiences while maintaining potential benefits. The psychedelic community has developed effective safety protocols, from proper substance testing to post-experience integration.
Abstract
Approximately 8.5 million Americans over the age of 12 endorsed past year psychedelic use in 2022, with 1.4 million individuals initiating use duri...
Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons
Journal of Neurochemistry – February 28, 2025
Summary
Serotonergic psychedelics like LSD rapidly alter how primary rat cortical neurons communicate. This Neuroscience and Neuropharmacology Research found these compounds reduced the fraction of chemical messengers released within 3-30 minutes. This transient effect, gone after 24 hours, varied. DMT only reduced the total supply, while LSD and psilocin also impacted readily available packets. Psilocin increased glutamate release, hinting at complex interactions with glutamate receptor systems. Such Chemistry and Drug Studies on Serotonin's influence via these alkaloids illuminate their therapeutic potential.
Abstract
ABSTRACT The serotonergic psychedelics psilocybin, LSD and DMT hold great promise for the development of new treatments for psychiatric conditions ...
Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
Clinical Pharmacology & Therapeutics – February 28, 2025
Summary
Paroxetine significantly reduces the unpleasant effects of LSD, a finding critical for psychedelic medicine. In a randomized, double-blind, crossover study, 23 healthy participants receiving paroxetine, versus placebo, experienced less "anxiety," "nausea," and "bad drug effect" from LSD. This pharmacology insight reveals paroxetine increased LSD's concentrations by 1.4-1.5 times, impacting its pharmacokinetics. Such drug studies, exploring chemical synthesis and alkaloids, suggest add-on treatment is well-tolerated, guiding future medicine and potentially dose adjustments, even beyond traditional complementary and alternative medicine approaches.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders...
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome.
Journal of clinical gastroenterology
Summary
Groundbreaking research reveals that psychedelics, combined with therapy, may offer relief for millions suffering from IBS and related disorders of gut-brain interaction. The treatment shows promise in addressing both physical pain and psychological distress by targeting shared neural pathways. Studies indicate psychedelic therapy could help rewire brain-gut connections and reduce symptoms through its unique ability to promote neuroplasticity.
Abstract
Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psyche...
Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ‐ and MES‐Induced Seizures in Mice via 5‐HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways
Pharmacology Research & Perspectives – February 25, 2025
Summary
A compelling discovery reveals psilocin, a known hallucinogen, exhibits anticonvulsant effects, offering new avenues in Epilepsy medicine. Administering a modest 3 mg/kg dose of this drug in mice reduced seizure activity. Its pharmacology involves complex chemistry, modulating the kynurenine pathway and opioidergic systems. This work, relevant to psychedelics and drug studies, shows effects mediated through the cannabinoid receptor (CB1) and other neurotransmitter receptors, influencing behavior for the 65 million people globally living with epilepsy.
Abstract
ABSTRACT Epilepsy, a chronic neurological disorder affecting around 65 million people globally, is characterized by recurrent, unprovoked epileptic...
Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution.
Journal of psychoactive drugs – February 13, 2025
Summary
Personal mindset plays a bigger role than physical environment in shaping profound psychedelic experiences. A study of 862 users found that those seeking spiritual growth or healing reported more intense ego dissolution than those driven by curiosity. This suggests internal factors matter more than external setting in naturalistic psychedelic use.
Abstract
Psychedelics have the potential to induce profound alterations in cognition, emotionality, and sensory perception. The quality and intensity of the...
Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use
British Journal of Pain – February 11, 2025
Summary
Among 466 adults with chronic pain, 86.3% reported decreasing or ceasing non-psychedelic substance use after self-treating with psychedelics. This included significant reductions in alcohol (71.1%) and prescription opioids (64.1%). While some increased illicit opioids or cannabis, 21.2% maintained reduced substance use for over 26 weeks. These findings in Psychiatry and Drug Studies suggest psychedelics offer novel potential in Medicine for chronic pain and substance use, necessitating rigorous Biochemical Analysis and Forensic Toxicology with advanced sensing techniques.
Abstract
Psychedelic substances have shown preliminary efficacy for several neuropsychiatric disorders and are currently being investigated for chronic pain...
Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent.
Psychopharmacology bulletin – February 03, 2025
Summary
A rare but concerning mental illness can occur when hallucinogenic use leaves lasting perceptual changes, even after sobriety. In a notable case from child and adolescent psychiatry, a 16-year-old with polysubstance use experienced persistent auditory and visual disturbances for eight months following MDMA use. Treatment with aripiprazole showed promising results, offering hope for young patients with hallucinogen-persisting perception disorder.
Abstract
Hallucinogen-persisting Perception Disorder (HPPD) is a rare condition characterized by the re-experiencing of one or more perceptual symptoms that...
Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.
The Journal of clinical psychiatry – February 05, 2025
Summary
Psychedelic therapy practitioners show surprising diversity in their treatment approaches, with some focusing on emotional-spiritual support while others emphasize biological effects. A survey of 40 experienced practitioners, who collectively guided over 1,600 psychedelic sessions, revealed that trust-building, spirituality, emotional environment, and handling challenging experiences were key factors. Those trained at specialized institutes like MAPS favored more emotion-centered approaches to supporting patients through psychedelic experiences.
Abstract
Objective: To assess the viewpoints of psychedelic practitioners in research settings on approaches to psychological support for psychedelic treatm...
Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.
Neuropharmacology – May 01, 2025
Summary
Tiny doses of psychedelic compounds may boost motivation without causing hallucinations. Scientists found that mice given ultra-low doses of 2,5-dimethoxy-4-propylamphetamine showed increased drive to work for rewards, but only in previously unmotivated animals. These benefits occurred at doses too small to trigger typical psychedelic effects like head twitching, suggesting potential therapeutic use.
Abstract
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT2A receptor agonists) such as LSD and psilocybin have shown therapeu...
Improved LC-MS Detection of Opioids, Amphetamines, and Psychedelics Using TrEnDi.
Journal of the American Society for Mass Spectrometry – March 05, 2025
Summary
A breakthrough chemical technique boosts detection of trace amounts of drugs by up to 24 times. Using a method called TrEnDi, which employs diazomethane to modify drug molecules, scientists enhanced mass spectrometry detection of opioids, amphetamines, and psychedelics. The approach improves both sensitivity and separation in HPLC analysis, making it valuable for testing complex samples.
Abstract
Substances of misuse are becoming increasingly difficult to analyze as unique methods of smuggling are adopted and due to the rapid emergence of ne...
Mushroom poisoning: An updated review
Turkish Journal of Emergency Medicine – January 01, 2025
Summary
Over 90% of mushroom poisoning deaths stem from cyclopeptide-amatoxin-containing species like *Amanita phalloides*. Distinguishing these deadly mushrooms from edible types is often impossible visually, making unintentional consumption a serious public health concern. This medical emergency highlights the critical need for effective medicine. Research into plant toxicity and pharmacological properties, including potential treatments like Silymarin or compounds from Berberine and alkaloids research, is vital for counteracting these potent mushroom toxins and improving patient outcomes.
Abstract
Abstract Mushrooms have been consumed frequently worldwide since ancient times. In addition to edible and harmless species, there are also poisonou...
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects
Journal of Psychoactive Drugs – January 29, 2025
Summary
A survey of 1,486 US adults (67.1% male) provides crucial insights into the evolving landscape of psychedelics and drug studies. Predominantly, people use MDMA and LSD recreationally, often orally. While acute effects like hallucinations and positive mood are common, residual headaches also occur. This psychology research offers a valuable scale for understanding public experiences with these chemical synthesis alkaloids. Deciphering this complex data helps us navigate the rabbit hole of diverse academic research themes surrounding psychedelics.
Abstract
The ever-changing landscape surrounding legality and accessibility of psychedelics and their increasing popularity make it imperative to better und...
Molecular Phylogeny and Morphology Reveal Four New Species of Conocybe (Bolbitiaceae, Agaricales) from the Qinghai-Xizang Plateau, China
Journal of Fungi – January 07, 2025
Summary
Seven *Conocybe* species, including four new ones, were identified on the Qinghai-Xizang Plateau, revealing fungi with potential for drug development. Collected over a decade, these *Agaricales* *taxa* contain alkaloids suitable for *chemical synthesis*, offering hope for psychiatric treatments. *Molecular phylogenetics* built a *phylogenetic tree*, confirming these unique *clades* within the *genus*. This enriches *biodiversity* and our understanding of *fungal biology and applications* in extreme *ecology*, marking a new *plateau* of discovery.
Abstract
The Qinghai-Xizang Plateau, known for its high altitude, geological history of plate collision, crustal uplift, and special ecology factors, provid...
What should constitute a control condition in psychedelic drug trials?
Nature. Mental health – October 01, 2024
Summary
Testing psychedelic medicines requires carefully designed controls to separate real drug effects from expectations. Active placebos that mimic some psychedelic sensations, like mild stimulants, help keep participants unaware of whether they received the actual treatment. This approach strengthens evidence about therapeutic benefits while accounting for the powerful role of mindset in psychedelic experiences.
Abstract
Over the past decade there has been a surge in interest in placebo-controlled trials using non-classical 3,4-methylenedioxymethamphetamine (MDMA) a...
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor
Journal of Child and Adolescent Psychopharmacology – January 06, 2025
Summary
Psychedelic therapies for adults, showing promise in psychopharmacology for conditions like PTSD and depression, are gaining traction in medicine and clinical psychology. Yet, for adolescents, there's a stark gap: zero recent trials. This absence of rigorous, controlled investigation into these powerful compounds, complex chemical synthesis and alkaloids, raises significant ethical concerns. Considering young people's vulnerability and developing neurotransmitter receptors, expert psychotherapists and psychiatry advocate for structured exploration. Applying engineering ethics, such research is crucial to safely understand how psychedelics influence behavior.
Abstract
Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress di...
A novel method for quantitative analysis of subjective experience reports: application to psychedelic visual experiences
Frontiers in Psychology – December 06, 2024
Summary
Psychedelics dramatically alter vision, but their specific visual effects vary consistently by substance. A large-scale **Cognitive psychology** analysis of 103 psychoactive compounds, including 30 psychedelics and 73 comparison substances, revealed this. Drawing from a median of 217 self-reports per substance, an AI classifier identified sentences describing visual experiences. This **Psychedelics and Drug Studies** research shows significant differences in how substances, even within psychedelics, affect vision and the types of visual changes, like movement or color. These findings advance **Psychology's** understanding of perception.
Abstract
Introduction Psychedelic compounds such as LSD, psilocybin, mescaline, and DMT can dramatically alter visual perception. However, the extent to whi...
Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.
Journal of the American Academy of Child and Adolescent Psychiatry – December 19, 2024
Summary
As mental health challenges surge among young people, medical experts are carefully examining the potential of psychedelic therapy for adolescents. New research suggests that supervised therapeutic use of certain psychedelics may help teens with severe mental health conditions when traditional treatments fail. The focus is on establishing strict safety protocols and ethical guidelines while recognizing that some teens already seek out these substances. Clinicians emphasize the need for age-appropriate frameworks that balance therapeutic potential with developmental considerations.
Abstract
We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged...
Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications.
ACS medicinal chemistry letters – December 12, 2024
Summary
Scientists have discovered innovative ways to enhance the therapeutic benefits of psilocin, the active compound in "magic mushrooms." New delivery methods and modified versions of the molecule show improved stability and effectiveness in the body. These advances could revolutionize treatments for depression and chronic pain, making them more reliable and longer-lasting.
Abstract
Psychedelic compounds, particularly psilocybin and psilocin, have shown significant therapeutic potential in treating neurological and psychiatric ...
Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
Journal of affective disorders – March 15, 2025
Summary
Recent findings reveal that psychedelic use among people with bipolar disorder led to reduced depression symptoms without triggering mania. Through Timeline Follow Back tracking, researchers found participants experienced fewer mental health symptoms and decreased cannabis use after psychedelic experiences. This suggests potential therapeutic benefits for mood disorders, challenging previous concerns about psychedelics in bipolar treatment.
Abstract
Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other ...
Sample composition and HIV prevention indicator differences using physical vs. virtual venue recruitment of men who have sex with men in San Francisco.
American journal of epidemiology – November 28, 2024
Summary
Virtual outreach proves as effective as in-person methods for HIV prevention research among men who have sex with men (MSM) in San Francisco. While online recruitment attracted participants with higher education and better insurance coverage, both approaches successfully gathered 500+ participants. Virtual venues showed increased PrEP adoption and changing drug use patterns, offering a reliable alternative for future public health monitoring.
Abstract
During the COVID-19 pandemic, the sampling method for the National HIV Behavioral Surveillance (NHBS) in San Francisco changed from physical venue ...
Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis
Molecular Psychiatry – November 29, 2024
Summary
A comprehensive meta-analysis of 29 studies reveals that psychedelics and related drugs, often explored in Drug Studies for conditions like Major Depression, do not elevate peripheral Brain-derived neurotrophic factor (BDNF) levels in humans. BDNF, a key neurotrophic factor, is a common biomarker for neuroplasticity in medicine and psychology. Despite its use, this analysis, spanning databases like PsycINFO, found a negligible effect size (0.024). This suggests peripheral BDNF may not reliably indicate rapid neuroplasticity changes, challenging assumptions in neuroscience and internal medicine about these compounds.
Abstract
Abstract Background Peripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting ...
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Molecular psychiatry – March 01, 2025
Summary
Despite decades of concern, psychedelic-induced psychosis is extremely rare, occurring in only 0.002% of general population cases. Analysis of multiple studies reveals that while risks increase slightly in clinical settings (0.2-0.6%), psychedelics appear safer than previously thought. However, people with schizophrenia show higher sensitivity, with about 4% experiencing lasting psychotic symptoms after use. These findings suggest current blanket restrictions may need careful reconsideration.
Abstract
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. Howe...
Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study.
Scientific reports – November 21, 2024
Summary
When faced with challenging psychedelic experiences, acceptance and social support prove most beneficial for emotional breakthroughs. Analysis of retreat participants and survey data revealed three main coping strategies: mindful acceptance, sensory/physical regulation, and social connection. Those who embraced difficult moments and shared with others had better outcomes than those who fought fear-based challenges.
Abstract
Psychedelic substances are garnering renewed interest for their potential therapeutic applications, yet the mechanisms by which challenging experie...
Structural insights into tryptamine psychedelics: The role of hydroxyl indole ring site in 5-HT2A receptor activation and psychedelic-like activity.
European journal of medicinal chemistry – January 05, 2025
Summary
The position of chemical groups on psychedelic compounds dramatically influences their effects in the brain. Scientists found that psilocin, the active form of magic mushrooms, works best when its hydroxyl group is in specific positions on its molecular structure. Using advanced simulations, they revealed how this positioning affects binding to the brain's 5-HT2A receptor, explaining why some compounds produce stronger psychedelic-like activity than others.
Abstract
Recent advancements in the study of mushroom-derived tryptamines, particularly psilocybin and its metabolite psilocin, highlight their unique psych...
Ayahuasca for the treatment of alcohol use disorder.
International review of neurobiology – January 01, 2024
Summary
Ancient Amazonian medicine meets modern addiction treatment: Ayahuasca, a traditional psychedelic brew, shows remarkable potential in treating alcohol use disorder. Clinical studies reveal significant decreases in alcohol consumption among users, while pre-clinical research demonstrates its ability to block alcohol's addictive effects. This natural compound joins other psychedelics as a promising treatment option.
Abstract
For decades, psychedelics have been investigated for the treatment of psychiatric disorders. Specifically, evidence suggests that psychedelics may ...
Proteomic analysis of psychedelic mushroom isolate and exploring potential antimicrobial peptides against bacteria.
Natural product research – November 05, 2024
Summary
Scientists discovered that magic mushrooms (Psilocybe cubensis) contain natural compounds that can fight harmful bacteria. Advanced protein analysis revealed several antimicrobial peptides that effectively combat S. aureus, a dangerous pathogen. These natural defenders could offer new ways to fight bacterial infections as traditional antibiotics lose effectiveness.
Abstract
Psychedelic mushrooms belonging to basidiomycota have gained prominence in research due to the range of hallucinogenic compounds. To combat the cha...
Snapshot of 5-HT 2A receptor activation in the mouse brain via IP 1 detection.
bioRxiv : the preprint server for biology – October 12, 2024
Summary
Scientists have discovered a new way to track how psychedelic drugs like LSD affect specific brain receptors. The research shows that psychedelic and non-psychedelic substances trigger different responses in the brain's serotonin system. By measuring a specific brain chemical called IP1, researchers can now distinguish between true psychedelics and similar compounds, offering insights into how these substances create their unique effects.
Abstract
The distinct subjective effects that define psychedelics such as LSD, psilocybin or DOI as drug class are causally linked to activation of the sero...
Psychoactive substances for the treatment of neuropsychiatric disorders.
Asian journal of psychiatry – November 01, 2024
Summary
Groundbreaking treatments using psychedelics are transforming mental healthcare. Ketamine offers rapid relief for severe depression, while MDMA shows remarkable success in treating PTSD. These substances, along with other psychedelics, work by altering brain chemistry and enhancing emotional processing. Clinical trials reveal significant improvements in patients with various neuropsychiatric disorders, often after just a few supervised sessions.
Abstract
In the contemporary landscape of psychiatric medicine, critical advancements have been noted in the utilization of psychoactive substances such as ...
Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.
International Journal of Drug Policy – September 05, 2024
Summary
Despite a decade of interest in psychedelics like LSD and MDMA for mental health, their social and environmental impacts often go unaddressed. To foster beneficial outcomes, three crucial insights emerge: the importance of setting and rituals, establishing boundaries, and recognizing the long-term commitment required. Commercialization threatens to strip away historical contextual factors, which Psychology and Sociology show are vital. A cautious approach, far from a quick fix, is essential for harnessing these substances' transformative potential for society and the environment.
Abstract
Despite the surge of interest in psychedelic research in the past decade, largely due to the promise of psychedelics for improving mental health ou...
Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report
Clinical Case Reports – August 30, 2024
Summary
Psychedelic-assisted therapy (PAT) demonstrates feasibility as a safe, home-based psychological intervention for severe existential distress in palliative care. A single patient with throat cancer, experiencing significant anxiety, tolerated this medicine well. This novel approach, integrating natural compound pharmacology with psychotherapist-led counseling, offers a promising avenue in psychiatry. Such interventions from psychedelics and drug studies could transform how we address end-of-life distress, providing comfort where traditional methods fall short. The successful application suggests a new frontier in medicine.
Abstract
Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a ...
Classic psychedelics and the treatment for alcoholism.
Progress in neuro-psychopharmacology & biological psychiatry – December 20, 2024
Summary
A single dose of classic psychedelics can significantly reduce alcohol dependence, offering hope for those struggling with alcohol use disorder. These substances work by rewiring neural pathways in the brain, helping patients break free from destructive drinking patterns. Clinical trials show remarkable success rates, with many participants maintaining sobriety after treatment. Unlike conventional therapies, psychedelic-assisted treatment appears to address the root causes of dependence, rather than just managing symptoms.
Abstract
Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-re...
Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.
Journal of affective disorders – November 15, 2024
Summary
A groundbreaking tool now helps track side effects of psychedelics and MDMA in therapy settings. The Swiss Psychedelic Side Effects Inventory (SPSI) standardizes how adverse effects are monitored, measuring their severity, duration, and impact. Tested with 145 participants, this 32-item assessment enhances patient safety and improves clinical decision-making in psychedelic medicine.
Abstract
Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effec...
Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT
OpenAlex – May 31, 2024
Summary
Psychedelics profoundly alter Consciousness. Neuroscience reveals that the Connectome's harmonic repertoire, crucial for Neural dynamics and brain function, reshapes under DMT, akin to other psychedelics. Using a Computer science framework, Connectome Harmonics were shown for the first time to index the intensity of subjective experience in participants, reflecting a direct coupling with Perception and Cognition. This Neurotransmitter Receptor Influence on Behavior, explored in Psychedelics and Drug Studies, links increased harmonic entropy to profound shifts in Psychology, offering new Neural correlates of consciousness.
Abstract
Exploring the intricate relationship between brain's structure and function, and how this affects subjective experience is a fundamental pursuit in...
Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
Addiction – June 06, 2024
Summary
The burgeoning push for psychedelic legalization, paralleling cannabis's journey, often uses poorly-evidenced therapeutic claims to establish de facto recreational markets. This observation, spanning Public administration, Business, and Political science, informs Psychedelics and Drug Studies. With four nations already permitting medical use, lessons from cannabis are vital. Effective Public relations must challenge industry hype and promote rigorous Chemical synthesis and alkaloids research. Coordinated government regulation is essential for responsible Legalization, preventing undue for-profit influence and managing Recreation within this diverse academic research theme.
Abstract
Abstract The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, ac...
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
Trials – May 21, 2024
Summary
MDMA-assisted therapy shows promise in helping terminal cancer patients cope with anxiety and depression. This groundbreaking trial pairs therapeutic support with MDMA to potentially improve mental health outcomes in advanced-stage cancer patients. Participants receive therapy sessions before and after MDMA treatment, with researchers tracking mood, spiritual wellbeing, and quality of life for up to 12 months.
Abstract
Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in thi...
Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
Journal of racial and ethnic health disparities – June 01, 2025
Summary
Income and education levels significantly influence how different racial groups respond to psychedelics for mental health benefits. While white individuals show reduced psychological distress with psychedelic use, minorities experience diminished returns - even at higher socioeconomic levels. Notably, educated, high-income Asian users reported increased distress, highlighting how ethnicity and inequality shape therapeutic outcomes.
Abstract
Growing evidence suggests that the race and ethnic minority population may experience fewer protective effects of psychedelics on mental health. Th...
Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Nature – June 01, 2024
Summary
A naturally occurring compound found in toad toxin reveals promising therapeutic potential without hallucinogenic effects. Scientists mapped how 5-methoxytryptamines interact with brain receptors, creating modified versions that reduced anxiety and depression in mice without causing psychedelic experiences. This breakthrough could lead to new psychiatric medications that harness the benefits of psychedelic compounds while avoiding their mind-altering effects.
Abstract
Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorde...
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
Psychopharmacology – June 01, 2024
Summary
Breakthrough treatments combining psychedelics with assisted therapy are showing remarkable promise in mental health care. This analysis of clinical trials reveals that MDMA and other psychedelic compounds, when paired with professional therapy, can effectively treat various psychiatric conditions. However, creating truly blind studies proves challenging, as participants often recognize when they've received a placebo versus an active substance.
Abstract
Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy ...
Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – August 01, 2024
Summary
The eye's retina may be the starting point for visual hallucinations, not just the brain as previously thought. Psychedelics like LSD affect specialized retinal cells called amacrine cells, disrupting normal visual perception before information even reaches the brain. This insight comes from studying both psychedelic experiences and rare conditions affecting the visual pathway, revealing how alterations in retinal processing can trigger vivid hallucinations.
Abstract
Psychedelics like LSD (Lysergic acid diethylamide) and psilocybin are known to modulate perceptual modalities due to the activation of mostly serot...
Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists
Journal of Medicinal Chemistry – April 22, 2024
Summary
Psychedelics show promise for mental health, influencing behavior via neurotransmitter receptor influence on behavior. Their pharmacology involves serotonin agonist activity at the 5-HT receptor. Through careful chemistry and chemical synthesis, a new class of serotonin agonists, 2,5-dimethoxyphenylpiperidines, has been discovered. Structure–activity relationship investigations, considering stereochemistry, identified LPH-5 as a selective 5-HT2A receptor agonist. This advances drug studies by providing new tools to understand how serotonin signaling affects the brain.
Abstract
Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) are showing promising results in clin...
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.
Expert opinion on emerging drugs – September 01, 2024
Summary
New hope emerges in the fight against alcohol use disorder as researchers evaluate over 20 promising drugs in clinical trials. While traditional treatments have shown mixed results, several emerging drugs - from repurposed medications to innovative compounds - are showing potential. Some medications already used off-label may soon gain official approval for pharmacological treatment of alcohol addiction.
Abstract
Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD...
Natural Product Synthesis in the 21st Century: Beyond the Mountain Top
ACS Central Science – February 14, 2024
Summary
Humanity's ancient curiosity about natural products, like alkaloids such as morphine, profoundly shaped medicine and fundamental chemistry. The premise of chemical synthesis emerged to overcome natural supply limits, revealing insights into organic chemistry. Though the field contracted about 20 years ago, advanced synthetic organic chemistry is poised for a resurgence. Future developments, integrating nanotechnology, biochemical engineering, and microbial natural products and biosynthesis, promise to transform how we create and utilize these vital compounds, delivering on their original potential.
Abstract
Research into natural products emerged from humanity's curiosity about the nature of matter and its role in the materia medica of diverse civilizat...
Pioneering Methods in Brain Optimization and Mental Health Treatment.
ACS medicinal chemistry letters – March 14, 2024
Summary
Breakthrough brain therapies combine AI-driven neurostimulation with carefully controlled psychedelic compounds to create personalized mental health treatments. Advanced algorithms analyze brain activity in real-time, allowing precise, non-invasive stimulation that works alongside natural compounds to optimize neural function. Early results show significant improvements in mood disorders and cognitive performance.
Abstract
This Patent Highlight explores ground-breaking advancements in neurostimulation, psychedelic therapy, and brain function optimization from recent i...
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
European Archives of Psychiatry and Clinical Neuroscience – February 27, 2024
Summary
The rapid antidepressant effects of Ketamine and Psychedelics are transforming Psychiatry. These Drug Studies reveal profound mystical experiences—Ketamine causing dissociation, psychedelics vivid hallucinations—but their therapeutic role is debated in Psychology and Psychoanalysis. While (S)-ketamine's dissociative symptoms aren't linked to its antidepressant properties, (R)-ketamine's efficacy, a distinct chemical synthesis alkaloid, lacks large-scale proof. Understanding how Neurotransmitter Receptor Influence on Behavior, like the 5-HT2A receptor for psychedelics, drives antidepressant action is crucial for psychotherapist practice.
Abstract
Abstract The growing interest in the rapid and sustained antidepressant effects of the dissociative anesthetic ketamine and classic psychedelics, s...
Expectancy Effects in Psychedelic Trials.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Positive expectations may significantly influence outcomes in psychedelic therapy, even with microdosing. When participants believe they'll benefit, they often do - highlighting the complex relationship between mind and medicine. Researchers found that proper trial design and blinding procedures are crucial, as the placebo effect can be particularly strong with psychedelics. This understanding helps optimize therapeutic benefits while improving future treatment protocols.
Abstract
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconside...
Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'.
Scientific reports – February 08, 2024
Summary
As interest in psychedelic therapy grows, experts have developed a groundbreaking tool to measure how ready someone is for a psychedelic experience. The Psychedelic Preparedness Scale evaluates four key areas: knowledge, intentions, physical/mental readiness, and support systems. Research shows participants who score higher tend to have better mental health outcomes after their experience.
Abstract
Preparing participants for psychedelic experiences is crucial for ensuring these experiences are safe and, potentially beneficial. However, there i...
Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.
Neuropsychiatric disease and treatment – January 01, 2024
Summary
Emerging research shows psychedelic therapy and trauma-focused psychotherapy share key healing mechanisms for PTSD treatment. A comprehensive review of patient experiences reveals both approaches rely on psychological safety, trust, and readiness to process trauma. Psychedelic treatments offer unique benefits through indirect processing and self-narrative reorganization, while maintaining core therapeutic principles.
Abstract
Post-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy inter...
Older adults in psychedelic-assisted therapy trials: A systematic review
Journal of Psychopharmacology – January 01, 2024
Summary
Psychedelic-assisted psychotherapy appears safe and well-tolerated for older adults, with no serious adverse events among the 10 participants for whom detailed safety data was available. This systematic review, using MEDLINE and other sources for Psychedelics and Drug Studies, analyzed 36 trials involving 1400 patients. Yet, only 19 (less than 1.4%) were aged 65 or older. While initial findings suggest these substances, often from chemical synthesis and alkaloids, modulating neurotransmitter receptors for behavioral influence, are safe, their potential in geriatric Psychology and Medicine warrants further exploration by psychotherapists.
Abstract
Background: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid di...
Aesthetic chills mitigate maladaptive cognition in depression
BMC Psychiatry – January 10, 2024
Summary
Profound emotional "chills" can positively reshape core self-beliefs in individuals with depression. A clinical psychology investigation involving 96 patients with major depressive disorder found that experiencing aesthetic chills, often characterized by shivers, shifted their negative self-schema. This psychological intervention, influencing cognitive processes, shows parallels to the profound mental shifts observed in psychedelics and drug studies. Such experiences offer a non-pharmacological treatment avenue for mental health, potentially aiding in depression management.
Abstract
Abstract Background Depression is a major global health challenge, affecting over 300 million people worldwide. Current pharmacological and psychot...
Psychedelic-like Activity of Norpsilocin Analogues
ACS Chemical Neuroscience – January 08, 2024
Summary
Norpsilocin, a primary metabolite of psychedelic mushrooms, typically lacks psychedelic effects *in vivo*, despite being a potent serotonin 2A receptor agonist *in vitro*. Its poor brain permeability was hypothesized. Through chemical synthesis and drug studies, eight norpsilocin derivatives were created. Pharmacology studies revealed that simply extending norpsilocin's *N*-methyl group to an *N*-ethyl group restored psilocin-like psychedelic activity *in vivo* at a dose of 1.4 mg/kg. Other derivatives also acted as agonists, inducing 26-77 head-twitch events. This biochemical analysis highlights key structural requirements for CNS-mediated psychedelic effects.
Abstract
Primary metabolites of mushroom tryptamines, psilocybin and baeocystin (i.e., psilocin and norpsilocin), exhibit potent agonist activity at the ser...
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – March 01, 2024
Summary
Inhaled DMT shows promise as a rapid-acting psychedelic, with effects lasting just 10 minutes compared to hours for similar compounds. In this groundbreaking clinical trial, researchers tested different doses of N,N-Dimethyltryptamine in healthy volunteers, finding it both safe and well-tolerated. The dose-response study revealed positive mood effects and manageable physical responses, suggesting potential for treating mood disorders efficiently.
Abstract
Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, a...
Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.
Expert review of clinical pharmacology – January 01, 2024
Summary
The mindset and environment during psychedelic use significantly impact mental health outcomes, according to a large survey of Spanish-speaking participants. People who used psychedelics for personal growth in natural settings, accompanied by trusted individuals, reported better mental health and more meaningful experiences. Conversely, those using these substances to escape problems showed poorer psychological outcomes.
Abstract
In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate v...
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2023
Summary
Despite promising results in psychedelic-assisted therapy (PAT), a striking 82% of clinical trials fail to verify if treatments were delivered as intended. Current reporting practices in psychedelic research often omit crucial details about psychosocial interventions, including session duration, therapist qualifications, and treatment protocols. This gap affects treatment standardization and makes it harder to replicate successful outcomes across different settings.
Abstract
Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychos...